News provided by Ro Dec 10, 2025, 09:00 ET Peer-reviewed study demonstrates patients treated with semaglutide through Ro achieve an average body weight loss of 16.6% over 68 weeks First study to evaluate both the long-term weight loss and safety outcomes of treatment with semaglutide via telehealth NEW YORK, Dec
Rajasekaran NS, Connell P, Christians ES, Yan LJ, Taylor RP, Orosz A, Zhang XQ, Stevenson TJ, Peshock RM, Leopold JA, Barry WH, Loscalzo J, Odelberg SJ, Benjamin IJ (2007) Human alphaB-crystallin mutation causes oxido-reductive stress and protein aggregation cardiomyopathy in mice
Weight beneficial treatments for type 2 diabetes
Individuals considering using a drug with GLP-1 should consult with their healthcare provider to discuss potential risks and benefits, especially since such off-label use has not been approved yet by the FDA